Statera Biopharma, Inc. (STAB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2021 | -174.4 Million USD | -1218.82% |
| 2020 | -13.22 Million USD | -294.97% |
| 2019 | -3.34 Million USD | 7.3% |
| 2018 | -3.61 Million USD | 62.79% |
| 2017 | -9.7 Million USD | -265.06% |
| 2016 | -2.65 Million USD | 78.96% |
| 2015 | -12.63 Million USD | -100.78% |
| 2014 | 1.62 Billion USD | 109.44% |
| 2013 | -17.26 Billion USD | 5.33% |
| 2012 | -18.23 Billion USD | -354.3% |
| 2011 | -4.01 Billion USD | -31193.23% |
| 2010 | -12.82 Million USD | 99.9% |
| 2009 | -12.82 Billion USD | 8.55% |
| 2008 | -14.02 Billion USD | -51854.61% |
| 2007 | -26.99 Million USD | -273.78% |
| 2006 | -7.22 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 Q2 | -4.12 Million USD | 53.68% |
| 2022 Q1 | -8.9 Million USD | 88.47% |
| 2022 Q3 | -5.15 Million USD | -25.09% |
| 2021 Q4 | -77.23 Million USD | -507.23% |
| 2021 Q2 | -6.6 Million USD | -24.94% |
| 2021 Q3 | -12.71 Million USD | -92.57% |
| 2021 FY | -174.4 Million USD | -1218.82% |
| 2021 Q1 | -5.28 Million USD | -24.98% |
| 2020 Q4 | -4.22 Million USD | 25.51% |
| 2020 Q1 | -648.11 Thousand USD | 0.0% |
| 2020 Q2 | -369.83 Thousand USD | 42.94% |
| 2020 FY | -13.22 Million USD | -294.97% |
| 2020 Q3 | -5.67 Million USD | -1435.49% |
| 2019 Q3 | -449.91 Thousand USD | 27.06% |
| 2019 FY | -3.34 Million USD | 7.3% |
| 2019 Q1 | -872.94 Thousand USD | 0.0% |
| 2019 Q2 | -616.82 Thousand USD | 29.34% |
| 2018 Q3 | -1.1 Million USD | -29.78% |
| 2018 FY | -3.61 Million USD | 62.79% |
| 2018 Q1 | -1.22 Million USD | 0.0% |
| 2018 Q2 | -851.03 Thousand USD | 30.51% |
| 2017 FY | -9.7 Million USD | -265.06% |
| 2017 Q2 | -5.61 Million USD | -237.37% |
| 2017 Q1 | -1.66 Million USD | 0.0% |
| 2017 Q3 | -1.26 Million USD | 77.54% |
| 2016 Q3 | 1.13 Million USD | 159.99% |
| 2016 Q2 | -1.89 Million USD | -184.14% |
| 2016 Q1 | -667.93 Thousand USD | 0.0% |
| 2016 FY | -2.65 Million USD | 78.96% |
| 2015 FY | -12.63 Million USD | -100.78% |
| 2015 Q3 | -3.12 Million USD | 29.8% |
| 2015 Q2 | -4.44 Million USD | -21.76% |
| 2015 Q1 | -3.65 Million USD | 0.0% |
| 2014 Q3 | -4.09 Million USD | -3.41% |
| 2014 Q1 | -1.58 Million USD | 0.0% |
| 2014 FY | 1.62 Billion USD | 109.44% |
| 2014 Q2 | -3.96 Million USD | -149.86% |
| 2013 Q3 | -4.09 Million USD | -34.49% |
| 2013 Q2 | -3.04 Million USD | 68.84% |
| 2013 FY | -17.26 Billion USD | 5.33% |
| 2013 Q1 | -9.76 Million USD | 0.0% |
| 2012 Q3 | -10.87 Million USD | -114.19% |
| 2012 Q2 | -5.07 Million USD | 5.73% |
| 2012 Q1 | -5.38 Million USD | 0.0% |
| 2012 FY | -18.23 Billion USD | -354.3% |
| 2011 Q3 | - USD | -100.0% |
| 2011 Q1 | -5.49 Million USD | 0.0% |
| 2011 FY | -4.01 Billion USD | -31193.23% |
| 2011 Q2 | 11.36 Million USD | 306.73% |
| 2010 Q3 | -7.2 Million USD | 0.0% |
| 2010 FY | -12.82 Million USD | 99.9% |
| 2010 Q1 | -3.36 Million USD | 0.0% |
| 2010 Q2 | - USD | 100.0% |
| 2009 FY | -12.82 Billion USD | 8.55% |
| 2009 Q2 | -6.47 Million USD | -118.89% |
| 2009 Q1 | -2.95 Million USD | 0.0% |
| 2009 Q3 | -5.18 Million USD | 19.88% |
| 2008 Q1 | -3.97 Million USD | 0.0% |
| 2008 FY | -14.02 Billion USD | -51854.61% |
| 2008 Q3 | -2.83 Million USD | 25.65% |
| 2008 Q2 | -3.8 Million USD | 4.09% |
| 2007 Q3 | -17.7 Million USD | -128.41% |
| 2007 Q1 | -4.1 Million USD | 0.0% |
| 2007 FY | -26.99 Million USD | -273.78% |
| 2007 Q2 | -7.75 Million USD | -88.82% |
| 2006 FY | -7.22 Million USD | 0.0% |
| 2006 Q2 | -1.27 Million USD | 0.0% |
| 2006 Q3 | -1.58 Million USD | -24.22% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -22805.645% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -1920.484% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -467.199% |
| Biora Therapeutics, Inc. | -124.11 Million USD | -40.521% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -984.763% |
| Better Therapeutics, Inc. | -39.76 Million USD | -338.652% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -824.458% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -849.008% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -387.024% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -383.594% |
| Evelo Biosciences, Inc. | -114.52 Million USD | -52.286% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -7657.473% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | -133.309% |
| Galera Therapeutics, Inc. | -59.08 Million USD | -195.197% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -2812.499% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -719.048% |
| Molecular Templates, Inc. | -8.12 Million USD | -2046.826% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -1049.149% |
| NexImmune, Inc. | -32.34 Million USD | -439.222% |
| Orgenesis Inc. | -55.36 Million USD | -215.038% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -590.37% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -223451.487% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -853.585% |
| Scopus BioPharma Inc. | -11.6 Million USD | -1402.246% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 69.554% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -4760.874% |
| Trevena, Inc. | -40.28 Million USD | -332.893% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -306233.938% |
| Vaccinex, Inc. | -20.25 Million USD | -761.232% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -14653.946% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -241.588% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -2142.562% |